Table 3.
Ongoing clinical trials investigating combinations of locoregional therapy and immune checkpoint inhibitors
|
NCT
|
Phase
|
Locoregional Therapy
|
Systemic Therapy
|
Endpoint
|
Estimated End of Trial
|
| NCT03817736 | 2 | TACE + SBRT | ICI | Sequential | February 2024 |
| NCT03638141 | 2 | DEB-TACE | DURVALUMAB + TREMELIMUMAB | Sequential | November 2023 |
| NCT03143270 | 1 | TACE | NIVOLUMAB | Combination | April 2022 |
| NCT03572582 | 2 | TACE | NIVOLUMAB | Combination | June 2023 |
| NCT03397654 | 1/2 | TACE | PEMBROLIZUMAB | Sequential | December 2021 (results awaited) |
| NCT03383458 | 3 | Curative resection or ablation | NIVOLUMAB | Adjuvant | June 2025 |
| NCT02821754 | 2 | TACE, RFA, Cryo | DURVALUMAB, TREMELIMUMAB | Combination | December 2022 |
| NCT03033446 | 2 | Y90-Radioembolization | NIVOLUMAB | Combination | December 2021 (results awaited) |
| NCT03099564 | 1 | Y90-Radioembolization | PEMBROLIZUMAB | Combination | July 2022 |
| NCT03259867 | 2 | TATE | NIVOLUMAB OR PEMBROLIZUMAB | Combination | December 2022 |
| NCT03937830 | 2 | TACE | DURVALUMAB + TREMELIMUMAB + BEVACIZUMAB | Combination | December 2023 |
| NCT03778957 | 3 | TACE | DURVALUMAB or DURVALUMAB + BEVACIZUMAB | Combination | August 2024 |
| NCT04340193 | 3 | TACE | NIVOLUMAB + IPILIMUMAB or NIVOLUMAB MONOTHERAPY or DOUBLE PLACEBO | Combination | January 2024 |
| NCT04246177 | 3 | TACE | PEMBROLIZUMAB + LENVATINIB | Combination | December 2029 |
| NCT04268888 | 2/3 | TACE/TAE | NIVOLUMAB | Combination | June 2026 |
| NCT05162898 | N/A | RFA | TORIPALIMAB + LENVATINIB | Combination | December 2025 |
| NCT05057845 | 2 | Cryo | TISLELIZUMAB + LENVATINIB | Combination | September 2024 |
| NCT04988945 | 2 | TACE + SBRT | DURVALUMAB + TREMELIMUMAB | Sequential (for downstaging) | December 2026 |
| NCT04727307 | 2 | RFA | ATEZOLIZUMAB (neoadjuvant) + ATEZOLIZUMAB-BEVACIZUMAB (adjuvant) | Combination | July 2027 |
| NCT04663035 | 2 | Ablation | TISLELIZUMAB | Combination | December 2025 |
| NCT04652440 | 1/2 | RFA | TISLELIZUMAB | Combination | November 2023 |
| NCT04639180 | 3 | Curative resection or ablation | CAMRELIZUMAB + APATINIB | Adjuvant | July 2024 |
| NCT04220944 | 1 | MWA+TACE | SINTILIMAB | Combination | September 2022 |
| NCT04102098 | 3 | Surgical resection or ablation | ATEZOLIZUMAB+ BEVACIZUMAB | Adjuvant | July 2027 |
| NCT03867084 | 3 | Surgical resection or local ablation | PEMBROLIZUMAB | Adjuvant | June 2025 |
| NCT03864211 | 1/2 | Thermal ablation (MWA or RFA) | TORIPALIMAB | Combination | June 2023 |
| NCT03753659 | 2 | MWA or RFA or Brachytherapy or TACE | PEMBROLIZUMAB | Combination | June 2024 |
| NCT03630640 | 2 | Electroporation | NIVOLUMAB (neoadjuvant & adjuvant) | Combination | November 2023 |
NCT: Number of the clinical trial (Clinicaltrials.gov); TACE: Transarterial chemoembolization; SBRT: Stereotactic body radiotherapy; DEB: Drug eluting bead; RFA: Radiofrequency ablation; Cryo: Cryoablation; TATE: Transarterial tirapazamine embolization; TAE: Transarterial embolization; MWA: Microwave ablation.